vTv Therapeutics/$VTVT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About vTv Therapeutics
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
Ticker
$VTVT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
23
ISIN
US9183852048
Website
vTv Therapeutics Metrics
BasicAdvanced
$104M
-
-$2.84
0.60
-
Price and volume
Market cap
$104M
Beta
0.6
52-week high
$26.99
52-week low
$12.12
Average daily volume
4.6K
Financial strength
Current ratio
7.395
Quick ratio
7.196
Total debt to equity
1.405
Profitability
EBITDA (TTM)
-24.98
Gross margin (TTM)
-68,764.71%
Net profit margin (TTM)
-109,935.29%
Operating margin (TTM)
-147,388.24%
Management effectiveness
Return on assets (TTM)
-36.33%
Return on equity (TTM)
-131.31%
Valuation
Price to revenue (TTM)
6,088.304
Price to book
13.07
Price to tangible book (TTM)
13.07
Price to free cash flow (TTM)
-4.24
Free cash flow yield (TTM)
-23.58%
Free cash flow per share (TTM)
-370.75%
Growth
Revenue change (TTM)
-98.30%
Earnings per share change (TTM)
-11.82%
3-year revenue growth (CAGR)
-84.98%
10-year revenue growth (CAGR)
-36.46%
3-year earnings per share growth (CAGR)
-34.16%
10-year earnings per share growth (CAGR)
-7.18%
What the Analysts think about vTv Therapeutics
Analyst ratings (Buy, Hold, Sell) for vTv Therapeutics stock.
vTv Therapeutics Financial Performance
Revenues and expenses
vTv Therapeutics Earnings Performance
Company profitability
vTv Therapeutics News
AllArticlesVideos
vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series
GlobeNewsWire·1 week ago
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
GlobeNewsWire·4 weeks ago
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for vTv Therapeutics stock?
vTv Therapeutics (VTVT) has a market cap of $104M as of June 18, 2025.
What is the P/E ratio for vTv Therapeutics stock?
The price to earnings (P/E) ratio for vTv Therapeutics (VTVT) stock is 0 as of June 18, 2025.
Does vTv Therapeutics stock pay dividends?
No, vTv Therapeutics (VTVT) stock does not pay dividends to its shareholders as of June 18, 2025.
When is the next vTv Therapeutics dividend payment date?
vTv Therapeutics (VTVT) stock does not pay dividends to its shareholders.
What is the beta indicator for vTv Therapeutics?
vTv Therapeutics (VTVT) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.